Catecholamine storage vesicles: Role of core protein genetic polymorphisms in hypertension

Current Hypertension Reports

Volumn 13, Issue 1, 2011, Pages 36-45

  Zhang, Kuixing ^a   Chen, Yuqing ^a   Wen, Gen ^a   Mahata, Manjula ^a   Rao, Fangwen ^a   Fung, Maple M ^a,c   Vaingankar, Sucheta ^a   Biswas, Nilima ^a   Gayen, Jiaur R ^a   Friese, Ryan S ^a   Mahata, Sushil K ^a,c   Hamilton, Bruce A ^a   O'Connor, Daniel T ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Blood pressure; Catecholamine; CHGA; CHGB; Genetics; Granins; Heritability; Hypertension; SCG2

Indexed keywords

ADENINE; ALBUMIN; CATECHOLAMINE; CHROMOGRANIN A; CHROMOGRANIN B; CORE PROTEIN; CYTOSINE; ISOPROSTANE; SECRETOGRANIN II; THYMINE;

3' UNTRANSLATED REGION; ADRENERGIC SYSTEM; ARTICLE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; GENETIC VARIABILITY; HAPLOTYPE; HERITABILITY; HUMAN; HYPERTENSION; INTRON; NONHUMAN; OPEN READING FRAME; PHENOTYPE; POPULATION GENETICS; PROMOTER REGION; PROTEIN FUNCTION;

ANALYSIS OF VARIANCE; CATECHOLAMINES; CHI-SQUARE DISTRIBUTION; CHROMOGRANIN A; CHROMOGRANIN B; CHROMOGRANINS; CONFIDENCE INTERVALS; DISEASE PROGRESSION; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; HYPERTENSION; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS; SECRETOGRANIN II;

EID: 79551512487     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0170-y     Document Type: Article

References (64)

1. NR Mahapatra M Mahata SK Mahata DT O'Connor 2006 The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters J Hypertens 24 895 904 1:CAS:528:DC%2BD28XjsVeltbs%3D 10.1097/01.hjh.0000222760.99852.e0 16612252 (Pubitemid 43670461)
2. JS Videen MS Mezger YM Chang DT O'Connor 1992 Calcium and catecholamine interactions with adrenal chromogranins. Comparison of driving forces in binding and aggregation J Biol Chem 267 3066 3073 1:CAS:528:DyaK38XhsVCmtLY%3D 1737762
3. NR Mahapatra DT O'Connor SM Vaingankar, et al. 2005 Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog J Clin Invest 115 1942 1952 1:CAS:528:DC%2BD2MXlvF2qtLo%3D 10.1172/JCI24354 16007257 (Pubitemid 40979734)
4. SH Yoo SH So YH Huh HY Park 2002 Inositol 1, 4, 5-trisphosphate receptor/Ca(2+) channel modulatory role of chromogranins A and B Ann N Y Acad Sci 971 300 310 1:CAS:528:DC%2BD38XovFalsLg%3D 10.1111/j.1749-6632.2002.tb04484. x 12438140
5. SK Mahata CA Kozak J Szpirer, et al. 1996 Dispersion of chromogranin/secretogranin secretory protein family loci in mammalian genomes Genomics 33 135 139 1:CAS:528:DyaK28XisFSmsbo%3D 10.1006/geno.1996.0171 8617499 (Pubitemid 26119407)
6. YH Huh SH Jeon SH Yoo 2003 Chromogranin B-induced secretory granule biogenesis: comparison with the similar role of chromogranin A J Biol Chem 278 40581 40589 1:CAS:528:DC%2BD3sXotFWgsr8%3D 10.1074/jbc.M304942200 12902350 (Pubitemid 37280870)
7. T Kim JH Tao-Cheng LE Eiden YP Loh 2001 Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis Cell 106 499 509 1:CAS:528:DC%2BD3MXmsFOiur4%3D 10.1016/S0092-8674(01)00459-7 11525735 (Pubitemid 32786993)
8. N Beuret H Stettler A Renold, et al. 2004 Expression of regulated secretory proteins is sufficient to generate granule-like structures in constitutively secreting cells J Biol Chem 279 20242 20249 1:CAS:528: DC%2BD2cXjs1WhtbY%3D 10.1074/jbc.M310613200 14996840 (Pubitemid 38623469)
9. L Taupenot KL Harper DT O'Connor 2003 The chromogranin-secretogranin family N Engl J Med 348 1134 1149 1:CAS:528:DC%2BD3sXit1Smur4%3D 10.1056/NEJMra021405 12646671 (Pubitemid 36337325)
10. K Tatemoto S Efendic V Mutt, et al. 1986 Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion Nature 324 476 478 1:CAS:528:DyaL2sXmtFGmug%3D%3D 10.1038/324476a0 3537810 (Pubitemid 17184167)
11. K Zhang F Rao G Wen, et al. 2006 Catecholamine storage vesicles and the metabolic syndrome: The role of the chromogranin A fragment pancreastatin Diabetes Obes Metab 8 621 633 1:CAS:528:DC%2BD28XhtlSks7nE 10.1111/j.1463-1326. 2006.00575.x 17026486 (Pubitemid 44515559)
12. JM Strub P Hubert G Nullans, et al. 1996 Antibacterial activity of secretolytin, a chromogranin B-derived peptide (614-626), is correlated with peptide structure FEBS Lett 379 273 278 1:CAS:528:DyaK28Xht1Wlurg%3D 10.1016/0014-5793(95)01529-9 8603705 (Pubitemid 26050042)
13. S Aardal KB Helle S Elsayed, et al. 1993 Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments J Neuroendocrinol 5 405 412 1:CAS:528:DyaK2cXht1KjsLo%3D 10.1111/j.1365-2826.1993.tb00501.x 8401564
14. SK Mahata DT O'Connor M Mahata, et al. 1997 Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist J Clin Invest 100 1623 1633 1:CAS:528:DyaK2sXmt1Cqtrc%3D 10.1172/JCI119686 9294131
15. SK Mahata M Mahata RJ Parmer DT O'Connor 1999 Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance J Biol Chem 274 2920 2928 1:CAS:528:DyaK1MXpsVekug%3D%3D 10.1074/jbc.274.5.2920 9915830 (Pubitemid 29075379)
16. S Benjannet R Leduc N Adrouche, et al. 1987 Chromogranin B (secretogranin I), a putative precursor of two novel pituitary peptides through processing at paired basic residues FEBS Lett 224 142 148 1:CAS:528:DyaL1cXhtVKkt78%3D 10.1016/0014-5793(87)80438-6 3678488
17. S Benjannet R Leduc C Lazure, et al. 1985 GAWK, a novel human pituitary polypeptide: isolation, immunocytochemical localization and complete amino acid sequence Biochem Biophys Res Commun 126 602 609 1:CAS:528:DyaL2MXptFKmtg%3D%3D 10.1016/0006-291X(85)90648-5 3970711 (Pubitemid 15173600)
18. S Kroesen J Marksteiner B Leitner, et al. 1996 Rat brain: distribution of immunoreactivity of PE-11, a peptide derived from chromogranin B Eur J Neurosci 8 2679 2689 1:STN:280:DyaK2s7ltVSntw%3D%3D 10.1111/j.1460-9568.1996.tb01563.x 8996818 (Pubitemid 27011345)
19. MH Metz-Boutigue Y Goumon K Lugardon, et al. 1998 Antibacterial peptides are present in chromaffin cell secretory granules Cell Mol Neurobiol 18 249 266 1:CAS:528:DyaK1cXitFaku70%3D 10.1023/A:1022573004910 9535293 (Pubitemid 28120173)
20. JM Strub P Garcia-Sablone K Lonning, et al. 1995 Processing of chromogranin B in bovine adrenal medulla. Identification of secretolytin, the endogenous C-terminal fragment of residues 614-626 with antibacterial activity Eur J Biochem 229 356 368 1:CAS:528:DyaK2MXltFOlurc%3D 10.1111/j.1432-1033.1995. tb20476.x 7744058
21. CJ Wiedermann 2000 Secretoneurin: a functional neuropeptide in health and disease Peptides 21 1289 1298 1:CAS:528:DC%2BD3cXotFGqt7k%3D 10.1016/S0196-9781(00)00271-0 11035217
22. MA Takiyyuddin AD Baron JH Cervenka, et al. 1991 Suppression of chromogranin-A release from neuroendocrine sources in man: pharmacological studies J Clin Endocrinol Metab 72 616 622 1:CAS:528:DyaK3MXlt1ygtL4%3D 10.1210/jcem-72-3-616 1671783
23. JE Dimsdale DT O'Connor M Ziegler P Mills 1992 Chromogranin A correlates with norepinephrine release rate Life Sci 51 519 525 1:CAS:528: DyaK38XkvVCjtLc%3D 10.1016/0024-3205(92)90029-O 1640800
24. MA Takiyyuddin RJ Parmer MT Kailasam, et al. 1995 Chromogranin A in human hypertension. Influence of heredity Hypertension 26 213 220 1:STN:280:DyaK2MzjtFymsQ%3D%3D 7607727
25. V Sanchez-Margalet M Valle JA Lobon, et al. 1995 Plasma pancreastatin-like immunoreactivity correlates with plasma norepinephrine levels in essential hypertension Neuropeptides 29 97 101 1:CAS:528:DyaK2MXosFOgt74%3D 10.1016/0143-4179(95)90090-X 7477767
26. V Sanchez-Margalet M Valle JA Lobon, et al. 1995 Increased plasma pancreastatin-like immunoreactivity levels in non-obese patients with essential hypertension J Hypertens 13 251 258 1:STN:280:DyaK2MzktFSjtg%3D%3D 7615956
27. DT O'Connor MT Kailasam BP Kennedy, et al. 2002 Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension J Hypertens 20 1335 1345 10.1097/00004872-200207000-00020 12131530 (Pubitemid 34925678)
28. F Rao G Wen JR Gayen, et al. 2007 Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension Circulation 115 2271 2281 1:CAS:528:DC%2BD2sXksFSjt70%3D 10.1161/CIRCULATIONAHA.106.628859 17438154 (Pubitemid 46685895)
29. DT O'Connor MA Takiyyuddin MP Printz, et al. 1999 Catecholamine storage vesicle protein expression in genetic hypertension Blood Press 8 285 295 10.1080/080370599439508 10803489
30. M Schober PR Howe G Sperk, et al. 1989 An increased pool of secretory hormones and peptides in adrenal medulla of stroke-prone spontaneously hypertensive rats Hypertension 13 469 474 1:CAS:528:DyaL1MXktVGhs7o%3D 2566578
31. RS Fries P Mahboubi NR Mahapatra, et al. 2004 Neuroendocrine transcriptome in genetic hypertension: multiple changes in diverse adrenal physiological systems Hypertension 43 1301 1311 1:CAS:528:DC%2BD2cXktFSksrs%3D 10.1161/01.HYP.0000127708.96195.E6 15166183 (Pubitemid 38691754)
32. TA Greenwood PE Cadman M Stridsberg, et al. 2004 Genome-wide linkage analysis of chromogranin B expression in the CEPH pedigrees: implications for exocytotic sympathochromaffin secretion in humans Physiol Genomics 18 119 127 1:CAS:528:DC%2BD2cXmtVWqs70%3D 10.1152/physiolgenomics.00104.2003 15138309 (Pubitemid 39319493)
33. TA Greenwood F Rao M Stridsberg, et al. 2006 Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion Physiol Genomics 25 470 479 1:CAS:528:DC%2BD28XmsFert70%3D 10.1152/physiolgenomics. 00295.2005 16554546 (Pubitemid 43764768)
34. MA Takiyyuddin L De Nicola FB Gabbai, et al. 1993 Catecholamine secretory vesicles. Augmented chromogranins and amines in secondary hypertension Hypertension 21 674 679 1:CAS:528:DyaK3sXkt1Gktr0%3D 8491501
35. EO Lillie DT O'Connor 2006 Early phenotypic changes in hypertension: a role for the autonomic nervous system and heredity Hypertension 47 331 333 1:CAS:528:DC%2BD28Xis1Kjtr4%3D 10.1161/01.HYP.0000203980.44717.aa 16446388 (Pubitemid 43740267)
36. R Kirchmair R Gander M Egger, et al. 2004 The neuropeptide secretoneurin acts as a direct angiogenic cytokine in vitro and in vivo Circulation 109 777 783 1:CAS:528:DC%2BD2cXhtFWltb0%3D 10.1161/01.CIR.0000112574.07422.C1 14970115 (Pubitemid 38222899)
37. D Boomsma A Busjahn L Peltonen 2002 Classical twin studies and beyond Nat Rev Genet 3 872 882 1:CAS:528:DC%2BD38Xotlersbk%3D 10.1038/nrg932 12415317 (Pubitemid 35303519)
38. B Folkow 1982 Physiological aspects of primary hypertension Physiol Rev 62 347 504 1:STN:280:DyaL387nsV2nsg%3D%3D 6461865
39. L Zhang F Rao J Wessel, et al. 2004 Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins Physiol Genomics 19 277 291 10.1152/physiolgenomics.00151.2004 15367723
40. NJ Schork SK Nath D Fallin A Chakravarti 2000 Linkage disequilibrium analysis of biallelic DNA markers, human quantitative trait loci, and threshold-defined case and control subjects Am J Hum Genet 67 1208 1218 1:CAS:528:DC%2BD3cXot1anuro%3D 10.1086/321201 11032785
41. BK Rana PA Insel SH Payne, et al. 2007 Population-based sample reveals gene-gender interactions in blood pressure in White Americans Hypertension 49 96 106 1:CAS:528:DC%2BD28XhtlSrs7nO 10.1161/01.HYP.0000252029.35106.67 17159089 (Pubitemid 46360347)
42. G Wen SK Mahata P Cadman, et al. 2004 Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology Am J Hum Genet 74 197 207 1:CAS:528:DC%2BD2cXhtlKiur4%3D 10.1086/381399 14740315 (Pubitemid 38168608)
43. E Halperin E Eskin 2004 Haplotype reconstruction from genotype data using Imperfect Phylogeny Bioinformatics 20 1842 1849 1:CAS:528:DC%2BD2cXntFahtr4%3D 10.1093/bioinformatics/bth149 14988101 (Pubitemid 39199048)
44. • Chen Y, Rao F, Rodriguez-Flores JL, et al.: Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure. Kidney Int 2008, 74:115-125. The authors uncovered a transcriptional basis whereby common variants and haplotypes in the CHGA promoter may be predictive of heritable changes in autonomic activity and BP.
45. DE Comings JP MacMurray 2000 Molecular heterosis: a review Mol Genet Metab 71 19 31 1:CAS:528:DC%2BD3cXms1yjsLw%3D 10.1006/mgme.2000.3015 11001792
46. • Chen Y, Rao F, Rodriguez-Flores JL, et al.: Naturally occurring human genetic variation in the 3′-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion. J Am Coll Cardiol 2008, 52:1468-1481. Here the authors defined the functional activity of common variant C+87T in the 3′-UTR of the CHGA mRNA, which has been associated with both BP elevation in the population and risk for hypertensive (nondiabetic) renal disease.
47. • Zhang K, Rao F, Wang L, et al.: Common functional genetic variants in catecholamine storage vesicle protein promoter motifs interact to trigger systemic hypertension. J Am Coll Cardiol 2010, 55:1463-1475. In this report, common variants and haplotypes of the CHGB promoter were functionally defined in transcriptional assays; such variants were strongly predictive of autonomic activity and BP in vivo.
48. JS Cui JL Hopper SB Harrap 2003 Antihypertensive treatments obscure familial contributions to blood pressure variation Hypertension 41 207 210 1:CAS:528:DC%2BD3sXnsFShsA%3D%3D 10.1161/01.HYP.0000044938.94050.E3 12574083 (Pubitemid 36204890)
49. TM Seasholtz J Wessel F Rao, et al. 2006 Rho kinase polymorphism influences blood pressure and systemic vascular resistance in human twins: role of heredity Hypertension 47 937 947 1:CAS:528:DC%2BD28XjsVeksL4%3D 10.1161/01.HYP.0000217364.45622.f0 16585408 (Pubitemid 44297566)
50. • Rao F, Zhang K, Khandrika S, et al.: Isoprostane, an "intermediate phenotype" for oxidative stress heritability, risk trait associations, and the influence of chromogranin B polymorphism. J Am Coll Cardiol 2010, 56:1338-1350. A common variant (C+84A) in the 3′-UTR of the CHGB mRNA was associated with an "oxidative stress" phenotype: isoprostane excretion. The variant acted by disrupting an A/U-rich mRNA stability element.
51. G Wen J Wessel W Zhou, et al. 2007 An ancestral variant of Secretogranin II confers regulation by PHOX2 transcription factors and association with hypertension Hum Mol Genet 16 1752 1764 1:CAS:528:DC%2BD2sXosFektbs%3D 10.1093/hmg/ddm123 17584765 (Pubitemid 47241834)
52. A Pattyn X Morin H Cremer, et al. 1997 Expression and interactions of the two closely related homeobox genes Phox2a and Phox2b during neurogenesis Development 124 4065 4075 1:CAS:528:DyaK2sXnt12gsLc%3D 9374403
53. F Rao J Wessel G Wen, et al. 2007 Renal albumin excretion: twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism Hypertension 49 1015 1031 1:CAS:528:DC%2BD2sXktFagsLg%3D 10.1161/HYPERTENSIONAHA.106.081679 17353515 (Pubitemid 351664306)
54. • Salem RM, Cadman PE, Chen Y, et al.: Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol 2008, 19:600-614. This was the initial report on the effect of CHGA polymorphisms on susceptibility to hypertensive renal disease in African Americans. The functional variant was at position C+87T in the CHGA mRNA.
55. EO Lillie M Mahata S Khandrika, et al. 2007 Heredity of endothelin secretion: human twin studies reveal the influence of polymorphism at the chromogranin A locus, a novel determinant of endothelial function Circulation 115 2282 2291 1:CAS:528:DC%2BD2sXksFSjt7o%3D 10.1161/CIRCULATIONAHA.106.648345 17438153 (Pubitemid 46685896)
56. • Chen Y, Mahata M, Rao F, et al.: Chromogranin A regulates renal function by triggering Weibel-Palade body exocytosis. J Am Soc Nephrol 2009, 20:1623-1632. The authors found that CHGA influenced renal function by triggering generalized exocytosis from Weibel-Palade bodies, the hormone storage granules in endothelial cells.
57. • Vaingankar SM, Li Y, Biswas N, et al.: Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. J Hypertens 2010, 28:817-825. CHGA expression displays paradoxic relationships with BP: though human essential hypertension is associated with elevated plasma CHGA, targeted ablation of the Chga locus in the mouse also results in hypertension. In this study, the authors used gene targeting and replacement to systematically vary the copy number of CHGA from 0 to 4 copies per diploid genome, and the results established biphasic effects of CHGA copy number on catecholamine storage and release as well as on BP.
58. • Gayen JR, Gu Y, O'Connor DT, Mahata SK: Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse. Endocrinology 2009, 150:5027-5035. Targeted ablation of the Chga locus results in systemic hypertension in the mouse; this study defined widespread effects of such genetic deletion upon both the sympathetic and parasympathetic branches of the autonomic nervous system.
59. • Dev NB, Gayen JR, O'Connor DT, Mahata SK: Chromogranin a and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment. Endocrinology 2010, 151:2760-2768. Adjustment of heart rate upwards or downwards in response to endogenous and exogenous cues (heart rate variability, HRV) reflects a healthy autonomic system. After targeted ablation of the Chga gene in the mouse, HRV declines; the trait can be "rescued" by replacement of the catestatin fragment of CHGA.
60. • Gayen JR, Saberi M, Schenk S, et al.: A novel pathway of insulin sensitivity in chromogranin A null mice: a crucial role for pancreastatin in glucose homeostasis. J Biol Chem 2009, 284:28498-28509. In the mouse, knockout of the Chga gene (Chga-/- genotype) results in a peculiar combination of elevated blood pressure coupled with enhanced insulin sensitivity, especially in the liver. Chga encodes a dysglycemic fragment, named "pancreastatin" ; administration of this peptide to Chga-/- mice reversed the insulin sensitivity of the knockout state.
61. • Friese RS, Gayen JR, Mahapatra NR, et al.: Global metabolic consequences of the chromogranin A-null model of hypertension: transcriptomic detection, pathway identification, and experimental verification. Physiol Genomics 2010, 40:195-207. Here the authors profiled the transcriptome in mice after targeted ablation of the Chga locus, and thereby identified global patterns of mRNA expression subserving enhanced insulin sensitivity in this animal model.
62. • Zhang K, Rao F, Rana BK, et al.: Autonomic function in hypertension: Role of genetic variation at the catecholamine storage vesicle protein chromogranin B (CHGB). Circ Cardiovasc Genet 2009, 2:46-56. Here the authors defined commonly occurring, natural genetic variation across the human CHGB locus, including promoter variants predicting elevated BP. In a complementary study, targeted ablation of the mouse Chgb locus resulted in systemic hypertension.
63. J Diaz-Vera YG Morales JR Hernandez-Fernaud, et al. 2010 Chromogranin B gene ablation reduces the catecholamine cargo and decelerates exocytosis in chromaffin secretory vesicles J Neurosci 30 950 957 1:CAS:528: DC%2BC3cXhtlKmtbc%3D 10.1523/JNEUROSCI.2894-09.2010 20089903
64. S Obermuller F Calegari A King, et al. 2010 Defective secretion of islet hormones in chromogranin-B deficient mice PLoS One 5 e8936 10.1371/journal.pone. 0008936 20126668